Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
P 2 (6)

Trial Status

Recruiting4
Unknown1
Active Not Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT06638931Phase 2RecruitingPrimary

Agnostic Therapy in Rare Solid Tumors

NCT07309770Phase 2RecruitingPrimary

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

NCT00082706Phase 2Active Not Recruiting

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

NCT06683846Phase 2Recruiting

Ivonescimab in the Treatment of Multiple Advanced Tumors

NCT06684327Phase 2Recruiting

Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

NCT04611724Phase 2UnknownPrimary

A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

Showing all 6 trials

Research Network

Activity Timeline